• SELECT SITE CURRENCY
Select a currency for use throughout the site
Global Ovarian Cancer Drugs Market 2011-2015
Infiniti Research Limited, August 2012, Pages: 36
TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Ovarian Cancer Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Eli Lilly and Co., GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals.
Other vendors mentioned in the report are Johnson & Johnson, Amgen Inc., Eisai Co. Ltd., BioNumerik Pharmaceuticals Inc., Endocyte Inc., Oasmia Pharmaceutical AB, Boehringer Ingelheim GmbH, and AstraZeneca plc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio today launched its report Global Ovarian Cancer Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said; ''The current trend witnessed by the Global Ovarian Cancer Drugs market is the use of combination therapies for the treatment of ovarian cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and the destruction of cancerous cells. The combination is chosen according to the size of the tumor and the risk of recurrence.''
According to the report, globally, there has been an increase in the number of women being diagnosed with ovarian cancer. The increase in the prevalence of ovarian cancer is owing to a variety of factors such as obesity, infertility, mutations in specific genes, early start of menstruation, and late start of menopause. Furthermore, the incidence of ovarian cancer increases with the rapidly expanding elderly population. Thus, with the increase in the prevalence of ovarian cancer, the demand for ovarian cancer drugs is also increasing.
Further, the report also discusses that one of the major challenges for the Global Ovarian Cancer Drugs market is the patent expiry of key ovarian cancer drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
01. Executive Summary
03. Market Coverage
04. Market Landscape
Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
Economic Indicators of Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
Major Vendors of the Global Cancer Drugs market
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Eli Lilly and Co.
15.2 GlaxoSmithKline plc
15.3 Bristol-Myers Squibb Co.
15.4 Roche Pharmaceuticals
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Ovarian Cancer Drugs Market 2011-2015 (US$ million)
Exhibit 2: Global Ovarian Cancer Drugs Market by Geographical Segmentation 2011
Exhibit 3: Global Cancer Drugs Market by Vendor Segmentation 2011
- Eli Lilly
- Bristol Myers Squibb
- Roche Pharmaceuticals